Campbell Shane Alden 4

What Happened

• Campbell Shane Alden, SVP, Proprietary Segment at West Pharmaceutical Services (WST), was granted two awards on 2026-03-01 totaling 3,822 restricted stock units (RSUs): 1,131 RSUs and 2,691 RSUs. Each award is reported at $0.00 (awarded, derivative award) in the Form 4.

Key Details

• Transaction date: 2026-03-01; Filing date: 2026-03-03 (filed within the required reporting window).
• Reported price: $0.00 for each grant (these are awards, not open-market purchases).
• Total RSUs awarded: 3,822 (1,131 + 2,691).
• Shares owned after transaction: not specified in the provided report.
• Footnotes: F1 — each RSU is a contingent right to one share of WST common stock; F2 — the RSUs vest in four equal annual installments beginning March 1, 2027; F3 — notes that any stock option vests in four equal annual installments beginning March 1, 2027 (no option exercise was reported here).

Context

• These transactions are awards of RSUs (derivative grants), not purchases or sales. RSUs represent a promise to deliver shares in the future if vesting conditions are met; they do not involve an immediate cash outlay or an immediate sale of shares. Such grants are common for compensation and do not, by themselves, indicate a buy or sell signal.